Establishment of cutoff values for anti-β2 glycoprotein I antibodies in women of reproductive age in Southwest China.
Anti-β2 glycoprotein I antibodies
Cutoff value
Women of reproductive age
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 09 2024
04 09 2024
Historique:
received:
04
03
2024
accepted:
28
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
epublish
Résumé
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and obstetric morbidity, with accurate laboratory examination of antiphospholipid antibodies (aPLs) being crucial for diagnosis. This study focused on anti-β2 glycoprotein I (aβ2GPI) antibodies and aimed to establish the first population-based cutoff values for aβ2GPI IgA/IgM/IgG antibodies in non-pregnant women of reproductive age in Southwest China. The study cohort comprised 181 healthy women of reproductive age for study. Blood samples were collected on an early morning fast. Anti-β2GPI antibodies including IgA, IgM and IgG were measured in serum using the HOB
Identifiants
pubmed: 39227704
doi: 10.1038/s41598-024-71549-2
pii: 10.1038/s41598-024-71549-2
doi:
Substances chimiques
beta 2-Glycoprotein I
0
Immunoglobulin M
0
Immunoglobulin G
0
Immunoglobulin A
0
Antibodies, Antiphospholipid
0
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20529Subventions
Organisme : Fundamental Research Funds for the Central Universities
ID : SCU2022F4080
Informations de copyright
© 2024. The Author(s).
Références
Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x (2006).
doi: 10.1111/j.1538-7836.2006.01753.x
pubmed: 16420554
Barbhaiya, M. et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 82(10), 1258–1270. https://doi.org/10.1136/ard-2023-224609 (2023).
doi: 10.1136/ard-2023-224609
pubmed: 37640450
Devreese, K. M. J., Ortel, T. L., Pengo, V. & de Laat, B. Laboratory criteria for antiphospholipid syndrome: Communication from the SSC of the ISTH. J. Thromb. Haemost. 16(4), 809–813. https://doi.org/10.1111/jth.13976 (2018).
doi: 10.1111/jth.13976
pubmed: 29532986
Abreu, M. M. et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun. Rev. 14(5), 401–414. https://doi.org/10.1016/j.autrev.2015.01.002 (2015).
doi: 10.1016/j.autrev.2015.01.002
pubmed: 25641203
Bernardoff, I. et al. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun. Rev. 21(1), 102913. https://doi.org/10.1016/j.autrev.2021.102913 (2022).
doi: 10.1016/j.autrev.2021.102913
pubmed: 34371159
Devreese, K. M. Antiphospholipid antibody testing and standardization. Int. J. Lab. Hematol. 36(3), 352–363. https://doi.org/10.1111/ijlh.12234 (2014).
doi: 10.1111/ijlh.12234
pubmed: 24750682
Favaloro, E. J. & Wong, R. C. Antiphospholipid antibody testing for the antiphospholipid syndrome: A comprehensive practical review including a synopsis of challenges and recent guidelines. Pathology 46(6), 481–495. https://doi.org/10.1097/pat.0000000000000142 (2014).
doi: 10.1097/pat.0000000000000142
pubmed: 25158812
Favaloro, E. J. & Wong, R. C. Laboratory testing for the antiphospholipid syndrome: Making sense of antiphospholipid antibody assays. Clin. Chem. Lab. Med. 49(3), 447–461. https://doi.org/10.1515/cclm.2011.064 (2011).
doi: 10.1515/cclm.2011.064
pubmed: 21275808
Bor, M. V., Jacobsen, I. S., Gram, J. B. & Sidelmann, J. J. Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: A systematic evaluation according to the guidelines. Lupus 27(9), 1446–1454. https://doi.org/10.1177/0961203318776105 (2018).
doi: 10.1177/0961203318776105
pubmed: 29848159
Bai, A. β2-glycoprotein I and its antibodies involve in the pathogenesis of the antiphospholipid syndrome. Immunol. Lett. 186, 15–19. https://doi.org/10.1016/j.imlet.2017.03.013 (2017).
doi: 10.1016/j.imlet.2017.03.013
pubmed: 28347805
Meroni, P. L. et al. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: In vitro and in vivo studies. Clin. Rev. Allergy Immunol. 32(1), 67–74. https://doi.org/10.1007/bf02686083 (2007).
doi: 10.1007/bf02686083
pubmed: 17426362
Banzato, A. et al. Antibodies to domain I of β(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb. Res. 128(6), 583–586. https://doi.org/10.1016/j.thromres.2011.04.021 (2011).
doi: 10.1016/j.thromres.2011.04.021
pubmed: 21620443
Devreese, K. M. J. Testing for antiphospholipid antibodies: Advances and best practices. Int. J. Lab. Hematol. 42, 49–58. https://doi.org/10.1111/ijlh.13195 (2020).
doi: 10.1111/ijlh.13195
pubmed: 32543059
World Health Organization. Women of reproductive age (15–49 years) population (thousands). https://www.who.int/data/gho/indicator-metadata-registry/imr-details/women-of-reproductive-age-(15-49-years)-population-(thousands ) (2024).
Ichihara, K. et al. The Asian project for collaborative derivation of reference intervals: (1) strategy and major results of standardized analytes. Clin. Chem. Lab. Med. 51(7), 1429–1442. https://doi.org/10.1515/cclm-2012-0421 (2013).
doi: 10.1515/cclm-2012-0421
pubmed: 23435151
ISO 15189:2022. Medical laboratories—Requirements for quality and competence. https://www.iso.org/standard/76677.html (2022).
Clinical and Laboratory Standards Institute (2015). Defining, establishing, and verifying reference intervals in the clinical laboratory, 3rd edition. CLSI document EP28-A3c. Wayne PA: Clinical and Laboratory Standards Institute. (2015).
Devreese, K. M. et al. Testing for antiphospholipid antibodies with solid phase assays: Guidance from the SSC of the ISTH. J. Thromb. Haemost. 12(5), 792–795. https://doi.org/10.1111/jth.12537 (2014).
doi: 10.1111/jth.12537
pubmed: 24589091
Devreese, K. M. & Van Hoecke, F. Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: More than calculating the in-house 99th percentiles, even for new automated assays. Thromb. Res. 128(6), 598–600. https://doi.org/10.1016/j.thromres.2011.06.023 (2011).
doi: 10.1016/j.thromres.2011.06.023
pubmed: 21762962
Chayoua, W. et al. The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J. Thromb. Haemost. 18(1), 169–179. https://doi.org/10.1111/jth.14633 (2020).
doi: 10.1111/jth.14633
pubmed: 31519058
Tincani, A., Andreoli, L., Casu, C., Cattaneo, R. & Meroni, P. Antiphospholipid antibody profile: Implications for the evaluation and management of patients. Lupus 19(4), 432–435. https://doi.org/10.1177/0961203310361491 (2010).
doi: 10.1177/0961203310361491
pubmed: 20353983
Grossi, V. et al. Two novel technologies for the detection of anti-cardiolipin and anti β2-glycoprotein antibodies in the real life: Chemiluminescent in comparison to the addressable laser bead immunoassays. Immunol. Investig. 49, 58–68. https://doi.org/10.1080/08820139.2019.1647233 (2020).
doi: 10.1080/08820139.2019.1647233
Vanoverschelde, L., Kelchtermans, H., Musial, J., de Laat, B. & Devreese, K. M. J. Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification. Res. Pract. Thromb. Haemost. 3(3), 515–527. https://doi.org/10.1002/rth2.12207 (2019).
doi: 10.1002/rth2.12207
pubmed: 31294336
pmcid: 6611479
Montaruli, B. et al. Anti-cardiolipin and anti-β2-glycoprotein I antibodies: Normal reference ranges in northwestern Italy. Lupus 21(7), 799–801. https://doi.org/10.1177/0961203312442260 (2012).
doi: 10.1177/0961203312442260
pubmed: 22635238
Reed, A. H., Henry, R. J. & Mason, W. B. Influence of statistical method used on the resulting estimate of normal range. Clin. Chem. 17(4), 275–284 (1971).
doi: 10.1093/clinchem/17.4.275
pubmed: 5552364
Dixon, W. Processing data for outliers. Biometrics 9(1), 74–89 (1953).
doi: 10.2307/3001634
Tukey, J. W. Exploratory Data Analysis 688 (Addison-Wesley, 1977).
Fontana, P., Poncet, A., Lindhoff-Last, E., de Moerloose, P. & Devreese, K. M. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J. Thromb. Haemost. 12(12), 2034–2037. https://doi.org/10.1111/jth.12732 (2014).
doi: 10.1111/jth.12732
pubmed: 25244443